NL-OMON25511
Recruiting
Not Applicable
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer (MBC) patients with ESR1 mutations in cellfree DNA: TAX-ESR1 study
Erasmus MC Cancer Institute, department of Medical Oncology0 sites185 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- breast cancer, metastasis, ESR1 mutations, chemotherapy
- Sponsor
- Erasmus MC Cancer Institute, department of Medical Oncology
- Enrollment
- 185
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female metastatic breast cancer patients with ER\-positive, HER2\- negative primary tumors;
- •\- Previous treatment with at least an aromatase inhibitor either in adjuvant and/or metastatic setting;
Exclusion Criteria
- •\- Previous chemotherapy for metastatic disease; completed within three years before inclusion
- •\- Patients with locally advanced disease, primary not amendable for resection or
- •radiation therapy with curative intent;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer (MBC) patients with ESR1 mutations in cell-free DNA: TAX-ESR1 study.Metastasis of breast cancer10006291NL-OMON46354Erasmus MC, Universitair Medisch Centrum Rotterdam175
Recruiting
Not Applicable
A multicenter study for validation of biomarkers and observational study for immune regulatory mechanisms in Juvenile Dermatomyositisjuvenile dermatomyositisrheumatic muscle disease1000381610028302NL-OMON50706niversitair Medisch Centrum Utrecht365
Completed
Not Applicable
A Multicenter Study on Biomarker Development Utilizing AI Multiomics for Patients with Advanced Solid Malignant TumorsAdvanced Solid MalignanciesJPRN-UMIN000043899ational Cancer Center Hospital East2,768
Active, not recruiting
Phase 1
A study to treat adult patients with a medicine who suffer from a low amount of remaining blood cancer cells after chemotherapy.minimal residual disease (MRD) of B-precursor ALLMedDRA version: 14.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-018314-75-PLAmgen Research (Munich) GmbH130
Active, not recruiting
Phase 1
A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia - MT103-203minimal residual disease (MRD) of B-precursor ALLMedDRA version: 12.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemiaEUCTR2010-018314-75-FRMicromet AG130